M Kyla Shea1, Stephen B Kritchevsky2, Richard F Loeser3, Sarah L Booth1. 1. USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts. 2. Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina. 3. Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Vitamin K has been implicated in chronic diseases associated with increased risk for mobility disability, such as osteoarthritis and cardiovascular disease. However, the association between vitamin K status and mobility disability is unknown. Therefore, we examined the association between vitamin K status and incident mobility disability in the Health, Aging, and Body Composition Study. METHODS: Plasma phylloquinone (vitamin K1) was categorized as <0.5, 0.5-<1.0 and ≥1.0 nmol/L (n = 1,323, 48% male). Plasma ucMGP, which increases when vitamin K status is low, was measured in 716 participants and categorized into tertiles. Mobility limitation and disability, defined as two consecutive semiannual reports of having any or a lot of difficulty walking a one-fourth mile or climbing 10 steps without resting, were assessed over a median 6-10 years of follow-up. Multivariate Cox proportional hazard models were used to evaluate the association between vitamin K status and incident mobility limitation and disability. RESULTS: Participants with plasma phylloquinone less than 0.5 nmol/L were more likely to develop mobility limitation and disability compared to those with at least 1.0 nmol/L (adjusted HR (95% CI) mobility limitation: 1.27 (1.05-1.53); disability: 1.34 (1.01-1.76)). After further adjustment for knee pain, the associations were partially attenuated (HR (95% CI) mobility limitation: 1.20 (0.99-1.45); disability: 1.26 (0.96-1.67)). Plasma ucMGP was not associated with incident mobility limitation, but was nonlinearly associated with incident mobility disability (HR (95% CI), compared to tertile 1: tertile 2 = 1.64 (1.19-2.27), tertile 3 = 1.17 (0.83-1.66), fully adjusted). CONCLUSION: Our results suggest vitamin K may be involved in the disablement process in older age. Future studies are needed to confirm our findings and clarify the underlying mechanism.
BACKGROUND: Vitamin K has been implicated in chronic diseases associated with increased risk for mobility disability, such as osteoarthritis and cardiovascular disease. However, the association between vitamin K status and mobility disability is unknown. Therefore, we examined the association between vitamin K status and incident mobility disability in the Health, Aging, and Body Composition Study. METHODS: Plasma phylloquinone (vitamin K1) was categorized as <0.5, 0.5-<1.0 and ≥1.0 nmol/L (n = 1,323, 48% male). Plasma ucMGP, which increases when vitamin K status is low, was measured in 716 participants and categorized into tertiles. Mobility limitation and disability, defined as two consecutive semiannual reports of having any or a lot of difficulty walking a one-fourth mile or climbing 10 steps without resting, were assessed over a median 6-10 years of follow-up. Multivariate Cox proportional hazard models were used to evaluate the association between vitamin K status and incident mobility limitation and disability. RESULTS: Participants with plasma phylloquinone less than 0.5 nmol/L were more likely to develop mobility limitation and disability compared to those with at least 1.0 nmol/L (adjusted HR (95% CI) mobility limitation: 1.27 (1.05-1.53); disability: 1.34 (1.01-1.76)). After further adjustment for knee pain, the associations were partially attenuated (HR (95% CI) mobility limitation: 1.20 (0.99-1.45); disability: 1.26 (0.96-1.67)). Plasma ucMGP was not associated with incident mobility limitation, but was nonlinearly associated with incident mobility disability (HR (95% CI), compared to tertile 1: tertile 2 = 1.64 (1.19-2.27), tertile 3 = 1.17 (0.83-1.66), fully adjusted). CONCLUSION: Our results suggest vitamin K may be involved in the disablement process in older age. Future studies are needed to confirm our findings and clarify the underlying mechanism.
Authors: Devyani Misra; Sarah L Booth; Irina Tolstykh; David T Felson; Michael C Nevitt; Cora E Lewis; James Torner; Tuhina Neogi Journal: Am J Med Date: 2013-03 Impact factor: 4.965
Authors: M Kyla Shea; Christopher J O'Donnell; Cees Vermeer; Elke J P Magdeleyns; Michael D Crosier; Caren M Gundberg; José M Ordovas; Stephen B Kritchevsky; Sarah L Booth Journal: J Nutr Date: 2011-05-31 Impact factor: 4.798
Authors: Ellen C M Cranenburg; Ralf Koos; Leon J Schurgers; Elke J Magdeleyns; Thea H M Schoonbrood; Robert B Landewé; Vincent M Brandenburg; Otto Bekers; Cees Vermeer Journal: Thromb Haemost Date: 2010-08-05 Impact factor: 5.249
Authors: Adriana J van Ballegooijen; Sinony R van Putten; Marjolein Visser; Joline W Beulens; Emiel O Hoogendijk Journal: Maturitas Date: 2018-04-30 Impact factor: 4.342
Authors: M Kyla Shea; Kathryn Barger; Sarah L Booth; Jifan Wang; Harold I Feldman; Raymond R Townsend; Jing Chen; John Flack; Jiang He; Bernard G Jaar; Mayank Kansal; Sylvia E Rosas; Daniel E Weiner Journal: Am J Clin Nutr Date: 2022-03-04 Impact factor: 8.472